Jim Eamma
Executive Director, Therapeutic Strategy Lead, Oncology & Hematology
Jim Eamma is Executive Director, Therapeutic Strategy Lead for Oncology and Hematology at Worldwide Clinical Trials. His experience in scientific and clinical research spans more than two decades and includes work in academic, clinical, and CRO settings. Although oncology is his primary area of focus, he has also worked on clinical trials in a number of therapeutic areas. His intimate knowledge of studies at the level of the investigative site gives him the logistical and practical perspective needed for effective leadership and oversight.
Ask Jim a question
Submit an RFP. Ask a Question
Jim Eamma has been engaged in biological investigation in oncology and molecular medicine for more than 25 years. He began his career at University of Texas Southwestern with laboratory and clinical research before moving on to project management and clinical oversight in the CRO industry. He has worked within multiple indications, serving leadership functions on clinical trials in all phases of clinical research. His primary area of study is oncology, a focus that began in 2006 with a project management role at Mary Crowley Cancer Research Centers, where he was engaged in approximately 50 leading early-phase studies across multiple indications. As Director of Network Research Operations with US Oncology, he oversaw more than 80 community-based oncology practices located in hundreds of clinical sites across the U.S., ensuring they were equipped with the tools, training, resources, information, and strategies necessary to conduct successful research programs. Since moving into the CRO space, he has led large, global Phase III studies but also specialized in dose escalation/expansion studies utilizing multiple, different designs i.e. 3+3, Accelerated Titration, mTPI, BOP2, BLRM, BOIN, etc. Additionally, Jim has worked on a number of late-phase and post-market studies, most notably the Bristol Myers Squibb program for Nivolumab (Opdivo).
Prior to his work in oncology, he supported several early-phase CNS studies investigating treatments impacting cognitive function of patients with schizophrenia or schizoaffective disorder. Currently, as Executive Director, Therapeutic Strategy Lead in Oncology and Hematology at Worldwide Clinical Trials, he nurtures and safeguards our sponsor relationships by developing effective clinical and operational strategies that allow sponsor's to achieve their study and corporate goals in a timely and cost effective manner.
Jim holds a Bachelor of Science in molecular biology from St. Andrews Presbyterian College in North Carolina.
